Adenosine deaminase co-immunization reverses age‑associated immunosenescence by restoring germinal center T follicular helper cell function

Older adults experience disproportionate morbidity and mortality from Clostridioides difficile infection (CDI); however, existing toxoid- and receptor binding domain (RBD)-based vaccines elicit suboptimal protection in aged hosts due to the age-associated defects in CD4 + T cell function, T follicular helper (T FH ) cell activation, and antibody quality. We evaluated whether adenosine deaminase (ADA), an enzymatic immune modulator that degrades immunosuppressive adenosine, and improves GC T FH differentiation and survival, could reverse these age-related impairments when co-delivered with DNA vaccine plasmids targeting toxin A and B RBDs (pRBD). In aged mice, pRBD vaccination alone produced markedly reduced toxin-specific effector/memory CD4 + T cells, diminished T FH activation, and poor toxin A neutralization compared to vaccinated young mice. Co-immunization with plasmid-encoded adenosine deaminase-1 (pADA) restored toxin-specific CD4 + T cell generation and cytokine production, activation-induced marker (AIM) T FH responses, and antibody-mediate toxin neutralization to levels comparable to young adults. Mechanistically, pADA co-immunization was associated with the reduction of CXCR4 on germinal center (GC) T FH cells—a phenotype previously linked to impaired GC positioning and diminished B cell help in aging—suggesting that ADA may improve humoral quality through modulation of CXCR4 expression, a pathway previously associated with GC T FH positioning. These immune enhancements corresponded with improved clinical outcomes in morbidity, mortality, and weight loss following C. difficile spore challenge of aged mice. Finally, pADA significantly reduced adenosine levels in aged lymph nodes, implicating a potential enzymatic-based regulation of GC immunosenescence. Together, these findings identify ADA as a metabolic adjuvant capable of reversing key features of vaccine immunosenescence and highlight adenosine-dependent CXCR4 regulation as a tractable axis for improving vaccine efficacy in older populations.

Authors

Institutions

Publication Details

Journal
GeroScience
Published
2026-11-17
DOI
https://doi.org/10.1007/s11357-026-02605-0
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adenosine deaminase co-immunization reverses age‑associated immunosenescence by restoring germinal center T follicular helper cell function

Arden O. Edgerton, Michele A. Kutzler, Jeffrey R. Maslanka, Kyra Woloszczuk et al.
1 links
GeroScience
T-cell and B-cell Immunology
article

Adenosine deaminase co-immunization reverses age‑associated immunosenescence by restoring germinal center T follicular helper cell function

Arden O. Edgerton, Michele A. Kutzler, Jeffrey R. Maslanka, Kyra Woloszczuk, Matthew R. Bell, Christian Sell, David Joyner, Joris Beld, Mohamad‐Gabriel Alameh, Elias K. Haddad, Michael C. Abt, Emily Nicole Bitsko
article en

Abstract

Older adults experience disproportionate morbidity and mortality from Clostridioides difficile infection (CDI); however, existing toxoid- and receptor binding domain (RBD)-based vaccines elicit suboptimal protection in aged hosts due to the age-associated defects in CD4 + T cell function, T follicular helper (T FH ) cell activation, and antibody quality. We evaluated whether adenosine deaminase (ADA), an enzymatic immune modulator that degrades immunosuppressive adenosine, and improves GC T FH differentiation and survival, could reverse these age-related impairments when co-delivered with DNA vaccine plasmids targeting toxin A and B RBDs (pRBD). In aged mice, pRBD vaccination alone produced markedly reduced toxin-specific effector/memory CD4 + T cells, diminished T FH activation, and poor toxin A neutralization compared to vaccinated young mice. Co-immunization with plasmid-encoded adenosine deaminase-1 (pADA) restored toxin-specific CD4 + T cell generation and cytokine production, activation-induced marker (AIM) T FH responses, and antibody-mediate toxin neutralization to levels comparable to young adults. Mechanistically, pADA co-immunization was associated with the reduction of CXCR4 on germinal center (GC) T FH cells—a phenotype previously linked to impaired GC positioning and diminished B cell help in aging—suggesting that ADA may improve humoral quality through modulation of CXCR4 expression, a pathway previously associated with GC T FH positioning. These immune enhancements corresponded with improved clinical outcomes in morbidity, mortality, and weight loss following C. difficile spore challenge of aged mice. Finally, pADA significantly reduced adenosine levels in aged lymph nodes, implicating a potential enzymatic-based regulation of GC immunosenescence. Together, these findings identify ADA as a metabolic adjuvant capable of reversing key features of vaccine immunosenescence and highlight adenosine-dependent CXCR4 regulation as a tractable axis for improving vaccine efficacy in older populations.

GeroScience
Children's Hospital of Philadelphia (US), Drexel University (US), University of Pennsylvania (US)
Pennsylvania Department of Health, University of Pennsylvania, Drexel University, INOVIO Pharmaceuticals, Abramson Cancer Center, National Institutes of Health, College of Medicine, Drexel University, National Institute on Aging, National Cancer Institute, National Institute of Allergy and Infectious Diseases
Good health and well-being
T-cell and B-cell Immunology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon